How can we better manage drug-resistant OAB/DO? ICI-RS 2018.

Christopher J Chermansky Brigitte Schurch Mohammad Sajjad Rahnamai Marcio Augusto AverbeckSachin MaldeVito ManciniFrancoise ValentiniArun Sahai

Published in: Neurourology and urodynamics (2020)

Further research is required to optimize these procedures and to better understand which patients will benefit from the various options available in managing refractory OAB.

Keyphrases

drug resistant
end stage renal disease
multidrug resistant
acinetobacter baumannii
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors